BMI$113.41-1.8%Cap: $3.3BP/E: 25.652w: [|----------](Apr 20)
Badger Meter (BMI) is a $3.3B water metering manufacturer — AMI hardware, BEACON SaaS, SmartCover sewer monitoring. Company guided FY2026 "relatively flat vs 2025" on April 17, a material downgrade from "high-single-digit" long-term framing. Stock fell another 30% the week of the guide and sits at a 52-week low. The April 20 10-Q surfaced three disclosures the 8-K didn't carry, and cross-ticker work on ROP, XYL, ITRI, and MWA shows BMI's narrative differs from every direct peer along three specific axes. ITRI's April 28 Q1 earnings disambiguate: sector digestion or BMI-specific.
What the filing says
Q1 2026 revenue $202.3M (-9.0% YoY). Utility Water -10.4%. Gross margin 41.7% vs 42.9% prior year. Diluted EPS $0.93 (-28.5%). Cash $205.5M, zero debt. Operating cash flow $33.9M (flat YoY despite the earnings decline; offset by payables surge).
Three items the 10-Q disclosed that the April 17 8-K did not:
- UDlive acquisition $100M + earnout (Note 8 Subsequent Events). Management calls the deal "not expected to have a material impact" — implying UDlive revenue is sub-$10M. That's a premium for a UK sewer monitoring platform.
- Buyback authorization doubled to $150M in February 2026 — after the Q4 guide-down. $38.2M deployed in Q1 at average $147.70/share; $114.7M remaining (≈3% of float at current prices).
- Raw material inventory +$15.3M QoQ; finished goods +$1.9M only. Demand weakness accumulates as finished goods. BMI's composition is pre-buy behavior, not demand collapse.
Management attributed gross margin compression to "lower sales volume and less favorable product mix" — not copper or tariffs. Prior quarters emphasized input costs. SaaS revenue (recognized over time) grew 22% YoY to $24.7M (12.2% of revenue from 9.1%). International grew 17% YoY (Europe +22%, Asia +35%) while US declined 12%. CEO and an officer bought $754K of stock in February at $145-150.
PRASA — the 1.6M-connection Puerto Rico project that underpins the H2 2026 recovery narrative — is not mentioned anywhere in the 10-Q body.
What the market thinks
Price $113.17 at 52-week low (1% of range). Analyst targets range $110-197 (mean $162.50). On the April 20 print alone, four firms split four ways: RBC $169 Outperform, Barclays $110 Underweight, Stifel $140 Buy, Baird $145 Outperform. The sell-side cannot agree.
Options skew is one-sided: P/C 0.18 — crowd positioned long for a bounce. Max pain $125 (+10.5%). IV 40.8% at 41st percentile — priced for noise, not event. Short interest 14.4%; days to cover 7.8.
Idiosyncratic variance jumped to 92% after the post-guide selloff — above the 75% threshold for a standalone idiosyncratic bet — but the market is treating BMI as damaged goods inside a sector trough.
Why the gap exists
Cross-corpus work across ROP, XYL, ITRI, MWA transcripts from October 2025 through April 2026 shows BMI is uniquely situated on three axes:
- Margin attribution. ROP (Neptune) attributed margin pressure to copper and tariff surcharges "largely bucket... evaded Q4." MWA's Q1 10-Q explicitly cites tariffs. XYL blames inflation and volume. Only BMI rotated from copper/tariff framing (prior quarters) to "volume and mix." When management rotates from "commodity transient" to "volume persistent" while peers rotate the other way, that is often an early share-loss tell.
- Inventory. ITRI drew total inventory DOWN $27.8M YoY. XYL drew raw materials DOWN $14M. MWA built both, consistent with a raised guide. BMI's raw-material-only build is differentiated.
- Language. "Customer short cycle order pacing" is BMI's wording. Zero matches for "pacing" across ROP/XYL/ITRI transcripts in the same window. Peers use "backlog normalization," "project timing," "lumpy pace" — all one-cycle-resolvable. "Pacing" connotes persistent.
The market has collapsed BMI into a generic "water metering cycle digestion" read. The cross-ticker evidence argues the pattern is BMI-specific.
Risks
- Squeeze. 14.4% short interest, 7.8 DTC, insider buys, buyback doubled, crowd P/C 0.18 — BMI is primed to pop on PRASA disclosure, UDlive close, or tariff refund quantification. Momentum crash risk applies: deeply negative-momentum names rally hardest when distress conditions reverse.
- ITRI miss (28% base rate). ITRI reports Q1 on April 28. Four consecutive beats (+15%, +22%, +4%, +12%). But CFO sold $339K in February; IV sits at the 82nd percentile. If ITRI acknowledges short-cycle weakness, the sector factor is confirmed and BMI's read flips from share-loser to first-to-admit.
- PRASA timeline slips. Absence of PRASA mention in the 10-Q is a yellow flag. A Q2 call that pushes PRASA to 2027 puts the "flat FY2026" guide at risk of further cuts.
- Momentum mean-reversion. BMI RSI 25 at 52-week low. ITRI RSI 78 near recent highs. Both legs at technical extremes before any catalyst fires.
Catalysts
- Apr 28 — ITRI Q1 2026 earnings. Primary disambiguation. Does Water Solutions segment language match BMI or the other peers?
- Apr 30 — UDlive acquisition closes. Cash funded.
- Late July — BMI Q2 2026 earnings. Share-loss test: does Utility Water decline YoY while ITRI Water Solutions grows?
- By July 31 — PRASA deployment disclosure expected (tracked as a prediction).
- Through Nov 2028 — Buyback authorization remaining $114.7M.
What would change our mind
- ITRI cites short-cycle or replacement-order weakness in Water Solutions segment on Apr 28 → sector factor confirmed → BMI is first-to-admit, not share-loser.
- BMI Q2 transcript shifts from "pacing" to "normalization" or "project timing" → language convergence with peers → share-loss hypothesis weakens.
- PRASA 8-K lands before July 31 with specific deployment dates → load-bearing assumption de-risked.
- ROP or XYL Q2 transcripts adopt "pacing" or "volume/mix" framing → BMI was first to say it, not the only one → sector factor.
- BMI Q2 earnings print Utility Water growing YoY and SaaS above 14% of revenue — growth story reasserts.
Evidence
| Evidence | Source | Credibility | LR |
|---|---|---|---|
| Q1 revenue -9% YoY ($202.3M); Utility Water -10.4%; EPS $0.93 (-28.5%) | BMI 10-Q 2026-03-31, Consolidated Statements of Operations | 0.95 | 0.5 |
| FY2026 guide "relatively flat vs 2025" | BMI 8-K 2026-04-17, Item 2.02 | 0.95 | 0.5 |
| UDlive acquisition $100M + 24-month EBITDA earnout | BMI 10-Q Note 8 Subsequent Events | 0.95 | 1.2 |
| Buyback authorization doubled to $150M Feb 2026; $114.7M remaining; Q1 avg price $147.70 | BMI 10-Q Stockholders Equity Note | 0.95 | 1.5 |
| Raw materials inventory +$15.3M QoQ; finished goods +$1.9M | BMI 10-Q Note 4 Inventories | 0.95 | 1.3 |
| GM compression attributed to "lower sales volume and less favorable product mix" | BMI 10-Q MD&A | 0.95 | 1.3 |
| SaaS (over-time) revenue +21.7% YoY to $24.7M; 12.2% of revenue | BMI 10-Q Revenue Disaggregation | 0.95 | 1.4 |
| International revenue +16.8% YoY (Europe +21.6%, Asia +35.1%, ME +29.6%) | BMI 10-Q Revenue by Geography | 0.95 | 1.3 |
| SCOTUS Feb 2026 ruling creates tariff refund opportunity; BMI "reviewing" | BMI 10-Q MD&A | 0.95 | 1.2 |
| "Customer short cycle order pacing" — zero matches across ROP/XYL/ITRI transcripts Oct 2025 - Apr 2026 | BMI 10-Q MD&A + cross-corpus transcript search | 0.90 | 1.6 |
| ROP Q3-Q4 2025: Neptune softness = copper/tariff surcharges "now normalizing" | ROP Q3 + Q4 2025 earnings transcripts | 0.90 | 1.5 |
| ITRI Q4 2025: "bookings much more normalized pace, lumpy always lumpy"; pipeline +27%; Outcomes backlog +58% | ITRI Q4 2025 earnings transcript | 0.90 | 1.2 |
| ITRI drew total inventory DOWN $27.8M YoY; XYL drew raw materials DOWN $14M YoY; MWA built both | ITRI/XYL/MWA most recent 10-Q filings | 0.95 | 1.4 |
| MWA raised FY2026 guidance by $20M midpoint; "healthy municipal replacement activity" | MWA Q1 2026 earnings release + call | 0.90 | 1.3 |
| CEO + officer bought $754K BMI stock Feb 2026 at ≈$145-150 | Form 4 2026-02-09, 2026-02-10 | 0.95 | 1.1 |
| PRASA not mentioned in 10-Q body | BMI 10-Q 2026-03-31 (absence) | 0.95 | 0.8 |
| Management incentive costs DOWN in Q1 | BMI 10-Q MD&A SEA bridge | 0.95 | 0.9 |
Net read: management actions convergently bullish, language uniquely pessimistic versus peers, market pricing a damaged-name read that cross-ticker evidence suggests is specific rather than structural. The disambiguation resolves at ITRI Q1 earnings on April 28.
// comments (0)